Guelph Researchers Working on New R. Equi Vaccine

Canadian researchers are working to develop a more effective vaccine for Rhodococcus equi that they hope will protect foals as young as three weeks of age from the harmful bacterium.

Rhodococcus equi lives in the soil and it can travel to, and multiply within, the foal's lungs, causing a deadly pneumonia if it is not caught and treated early. The mortality rate of foals with R. equi is 28%, and the bacterium is the leading cause of disease in foals between one and six months of age.

According to the latest edition of the University of Guelph's Equine Guelph Update, John F. Prescott, MA, VetMB, PhD, professor in the Department of Pathobiology at the Ontario Veterinary College, has been studying the process of how R. equi invades the foal's system, hiding and replicating inside the macrophage (white blood cells) cells that would typically fight off illness. "Not only does this process prevent the foal's immune system from responding appropriately, but additionally the bacterium seems to push the foal's immune response into developing in a way that is guaranteed to be unsuccessful in clearing infection," the newsletter reports.

The researchers are designing the vaccine to boost the young foal's ability to fight R. equi and prevent its replication within the macrophages.

The project is funded by the Natural Sciences and Engineering Council of Canada and Equine Guelph.

About the Author

Stephanie L. Church, Editor-in-Chief

Stephanie L. Church, Editor-in-Chief, received a B.A. in Journalism and Equestrian Studies from Averett College in Danville, Virginia. A Pony Club and 4-H graduate, her background is in eventing, and she is schooling her recently retired Thoroughbred racehorse, Happy, toward a career in that discipline. She also enjoys traveling, photography, cycling, and cooking in her free time.

Stay on top of the most recent Horse Health news with FREE weekly newsletters from Learn More